Severe sepsis and septic shock;Sepsis sévère et choc septique

Revue Medicale Suisse

Volumn 2, Issue 60, 2006, Pages 896-902

  Delaloye, Julie ^a   Baumgartner, Jean Daniel ^b   Calandra, Thierry ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b Hopital de Morges   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CLAVULANIC ACID; CORTICOSTEROID; DROTRECOGIN; FLUDROCORTISONE; GLYCOPEPTIDE; HYDROCORTISONE; IMIPENEM; INSULIN; MEROPENEM; PIPERACILLIN; PLACEBO; TAZOBACTAM; TETRACOSACTIDE; TICARCILLIN; TOLL LIKE RECEPTOR; ANTIDIABETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN C; RECOMBINANT PROTEIN;

BACTERIAL INFECTION; CAUSE OF DEATH; DRUG MIXTURE; DRUG TOLERANCE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL ADMISSION; HOST RESISTANCE; HUMAN; INSULIN TREATMENT; INTENSIVE CARE UNIT; PATHOGENESIS; REVIEW; SEPSIS; SEPTIC SHOCK; UNITED STATES; INCIDENCE; PROGNOSIS;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INTENSIVE CARE UNITS; PROGNOSIS; PROTEIN C; RECOMBINANT PROTEINS; SEPSIS; SHOCK, SEPTIC; UNITED STATES;

EID: 33646680528     PISSN: 16609379     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (23)

1. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644-55.
2. Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003;31:1250-6.
3. Parrillo JE, Parker MM, Natanson C, et al. Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy. Ann Intern Med 1990;113:227-42.
4. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003;348:1546-54.
5. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001;29:1303-10.
6. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: The CUB-Rea Network. Am J Respir Crit Care Med 2003;168:165-72.
7. Bochud PY, Calandra T. Pathogenesis of sepsis: New concepts and implications for future treatment. BMJ 2003;326:262-6.
8. Janeway CA, Jr., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002;20:197-216.
9. Kawai T, Akira S. Pathogen recognition with Toll-like receptors. Curr Opin Immunol 2005;17:338-44.
10. Martinon F, Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005;26:447-54.
11. Inohara N, Nunez G. NODs: Intracellular proteins involved in inflammation and apoptosis. Nat Rev Immunol 2003;3:371-82.
12. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996;86:973-83.
13. Cohen J, Brun-Buisson C, Torres A, Jorgensen J. Diagnosis of infection in sepsis: An evidence-based review. Crit Care Med 2004;32(Suppl.):S466-S94.
14. Bochud PY, Bonten M, Marchetti O, Calandra T. Antimicrobial therapy for patients with severe sepsis and septic shock: An evidence-based review. Crit Care Med 2004;32(Suppl.):S495-S512.
15. Marshall JC, Maier RV, Jimenez M, Dellinger EP. Source control in the management of severe sepsis and septic shock: An evidence-based review. Crit Care Med 2004;32(Suppl.):S513-S26.
16. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001;345:1368-77.
17. Van Den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359-67.
18. Van Den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med 2006;354:449-61.
19. Vincent JL, Sun Q, Dubois MJ. Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. Clin Infect Dis 2002;34:1084-93.
20. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001;344:699-709.
21. Abraham E, Laterre PF, Gang R, et al. Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death. N Engl J Med 2005;353:1332-41.
22. Annane D, Bellissant E, Bollaert PE, Briegel J, Keh D, Kupfer Y. Corticosteroids for severe sepsis and septic shock: A systematic review and meta-analysis. BMJ 2004;329:480.
23. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002;288:862-71.